Molecular Determinants Governing the Antitubercular Activity of Griselimycin
Abstract
ABSTRACT The emergence of drug-resistant strains of Mycobacterium tuberculosis makes anti-tubercular drug development a critical priority. Griselimycin is a cyclic peptide that targets the essential DNA sliding clamp of M. tuberculosis . While griselimycin is a promising antimycobacterial compound, its poorly understood structure-activity relationship has stalled derivatization. To investigate the contribution of each amino acid towards its activity, we assessed the antibiotic activity of an alanine scan library in M. tuberculosis . Incorporation of an N -terminal fluorophore enabled visualization of griselimycin accumulation inside of mycobacteria-infected macrophage cells. Derivatives containing altered cyclization chemistries, unnatural amino acids, expanded proline side chains, and alkyne handles were assessed, with a final design combining the most potent edits showing increased antibiotic activity. These findings present the comprehensive structure-activity investigation of griselimycin and can be used to rationally design future analogues. TABLE OF CONTENTS GRAPHIC
Fields of Study & Subjects
Tuberculosis Research and Epidemiology
HIV/AIDS drug development and treatment
Cancer therapeutics and mechanisms
Publication details
- Journal / source
- bioRxiv (Cold Spring Harbor Laboratory)
- Publisher
- openRxiv
- Publication date
- 22 March 2026
- Language
- EN
- Document type
- Preprint